Shares of BEAM stock opened at $23.30 on Monday. Beam Therapeutics has a fifty-two week low of $20.84 and a fifty-two week high of $49.50. The firm’s 50 day moving average price is $26.72 and ...

Bernstein analyst William Pickering maintained a Buy rating on Beam Therapeutics (BEAM – Research Report) today and set a price target of $37.00. The company’s shares closed yesterday at $25.54.

Yanan Zhu, an analyst from Wells Fargo, reiterated the Buy rating on Beam Therapeutics (BEAM – Research Report). The associated price target remains the same with $75.00. Discover outperforming ...

Sustainalytics’ Controversies Research identifies companies involved in incidents and events that may negatively impact stakeholders, the environment or the company’s operations. Controversies are ...

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.